Methods: United Network for Organ Sharing provided deidentified patient-level data. The study population included 8780 adult recipients (age > 12
years) having lung transplantation from January 1, 1999, to December 31, 2006. Multivariate logistic regression ( backward, P >. 10) was performed. Using the odds ratio for each PD0332991 nmr identified variable, an RSS was devised. The RSS included only pretransplant recipient variables and excluded donor variables.
Results: The strongest negative predictors of 1-year survival included extracorporeal membrane oxygenation, decreased estimated glomerular filtration rate, total bilirubin >2.0 mg/dL, recipient age, hospitalization at time of transplant, O(2) dependence, cardiac index <2, steroid dependence, donor: recipient weight ratio <0.7, all non-cystic fibrosis/chronic obstructive pulmonary disease etiologies, and female donor-to-male recipient. Threshold analysis identified 4 discrete groups: low risk, moderate, elevated risk, and high risk. The 1-year actuarial survival was 80.4% for the entire group, compared with 56.8% in the high-risk group (RSS > 7.2, n = 490; 6%).
Pretransplant recipient variables significantly influence both early and late survival following lung transplantation. Some patients face a higher than average risk of mortality during their first year posttransplant, which challenges the goals
of equitable organ allocation. RSS may improve organ find more Cyclosporin A solubility dmso allocation strategies by avoiding the potential negative impact of performing transplantation in extremely high-risk candidates.”
“Alzheimer’s disease (AD) is a neurodegenerative disorder characterized clinically by cognitive impairments that progress to dementia and death. The earliest symptoms of AD present as a relatively pure deficit in memory retrieval. Therefore, drug treatments that intervene in the early stages of AD by rescuing memory deficits could be promising therapies to slow, or even reverse progression of the disease. In this study, we tested the potential of systemic histone deacetylase inhibitor (HDACi) treatment to rescue cognitive deficits in a mouse model of AD. APPswe/PS1dE9 mice showed pronounced contextual memory impairments beginning at 6 months of age. Chronic HDACi injections (2-3 weeks) did not alter contextual memory formation in normal mice, but had profound effects in transgenic animals. Injections of sodium valproate, sodium butyrate, or vorinostat (suberoylanilide hydroxamic acid; Zolinzas (R)) completely restored contextual memory in these mutant mice. Further behavioral testing of the HDACi-treated transgenic mice showed that the newly consolidated memories were stably maintained over a 2-week period.